Navigation Links
Cumberland Pharmaceuticals Ranks as one of the Fastest Growing Companies in North America on Deloitte's 2011 Technology Fast 500™
Date:10/20/2011

NASHVILLE, Tenn., Oct. 20, 2011 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) today announced that it has been placed on Deloitte's 2011 Technology Fast 500 list, an annual ranking of the fastest growing technology, media, telecommunications, life sciences and clean technology companies in North America. Rankings are based on percentage of fiscal year revenue growth during the period from 2006 to 2010. Cumberland Pharmaceuticals grew 158% during this period.

"Cumberland Pharmaceuticals, like all 2011 Technology Fast 500 companies, has excelled in fostering innovation and channeling it into spectacular growth against the backdrop of one of the most challenging economies in history," said Eric Openshaw, vice chairman and U.S. technology, media and telecommunications leader, Deloitte LLP. "Deloitte recognizes Cumberland for its remarkable accomplishment."

"We are pleased to honor Cumberland Pharmaceuticals as a 2011 Technology Fast 500 company," said Mark Jensen, managing partner, technology and venture capital services,

Deloitte & Touche LLP. "As one of the fastest growing tech companies in North America, Cumberland has demonstrated excellence in technological innovation, entrepreneurship and rapid growth."

Cumberland Pharmaceuticals' Chief Executive Officer, A.J. Kazimi, credits a commitment to providing differentiated products that help improve patient care as the driving force behind the Company's 158% revenue growth. "We are honored to be recognized  among the innovative companies that comprise the 2011 Technology Fast 500 list," said Kazimi. "Our ability to deliver consistent revenue growth while providing real solutions for patients is a testament to the dedication and talent of our team. It is extremely rewarding to be honored by Deloitte for the second year in a row."

About Deloitte's 2011 Technology Fast 500

Technology Fast 500, which was conducted by Deloitte & Touche LLP, a subsidiary of Deloitte LLP, provides a ranking of the fastest growing technology, media, telecommunications, life sciences and clean technology companies – both public and private - in North America. Technology Fast 500 award winners are selected based on percentage fiscal year revenue growth from 2006 to 2010. In order to be eligible for Technology Fast 500 recognition, companies must own proprietary intellectual property or technology that is sold to customers in products that contribute to a majority of the company's operating revenues.

Companies must have base-year operating revenues of at least $50,000 USD or CD, and current-year operating revenues of at least $5 million USD or CD. Additionally, companies must be in business for a minimum of five years, and be headquartered within North America.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc. is a Tennessee-based specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. The Company's primary target markets include hospital acute care and gastroenterology. Cumberland's product portfolio includes Acetadote® (acetylcysteine) Injection for the treatment of acetaminophen poisoning, Caldolor® (ibuprofen) Injection, the first injectable treatment for pain and fever approved in the United States, and Kristalose® (lactulose) for Oral Solution, a prescription laxative. Cumberland is dedicated to providing innovative products that improve quality of care for patients. For more information on Cumberland, please visit www.cumberlandpharma.com.

Forward-Looking Statements

This press release contains forward-looking statements, which are subject to certain risks and reflect Cumberland's current views on future events based on what it believes are reasonable assumptions. No assurance can be given that these events will occur. As with any business, all phases of Cumberland's operations are subject to factors outside its control, and any one or combination of these factors could materially affect Cumberland's results of operations. These factors include market conditions, competition, an inability of manufacturers to produce Cumberland's products on a timely basis or a failure of manufacturers to comply with regulations applicable to pharmaceutical manufacturers, maintaining an effective sales and marketing infrastructure and other factors discussed in the Company's 2010 Annual Report on Form 10-K filed with the SEC on March 11, 2011. There can be no assurance that results anticipated by the Company will be realized or that they will have the expected effects. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date hereof. The Company does not undertake any obligation to publicly revise these statements to reflect events after the date hereof.


'/>"/>
SOURCE Cumberland Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cumberland Pharmaceuticals to Announce Third Quarter 2009 Financial Results on November 10, 2009
2. Cumberland Pharmaceuticals and Phebra Pty Ltd. Sign Exclusive Agreement for Commercialization of Caldolor(R) in Australia and New Zealand
3. Cumberland Pharmaceuticals Donates Caldolor(R) to Haitian Relief Effort
4. Cumberland Pharmaceuticals Reports 24% Increase in Net Revenue With Full Year 2009 Financial Results
5. Cumberland Pharmaceuticals Partners in Canada With Alveda Pharmaceuticals to Commercialize Caldolor(R)
6. Cumberland Pharmaceuticals To Announce First Quarter 2010 Financial Results on May 13, 2010
7. Cumberland Pharmaceuticals to Present at Jefferies Global Life Sciences Conference in New York on June 8, 2010
8. Cumberland Pharmaceuticals to Present at the Wells Fargo Healthcare Conference in Boston on June 23, 2010
9. Cumberland Pharmaceuticals Reports Second Quarter 2010 Financial Results
10. Cumberland Pharmaceuticals Announces Extension of FDA Review of Acetadote® Supplemental New Drug Application
11. Cumberland Pharmaceuticals and Phebra Pty Ltd. Announce the Launch of Acetadote® in Australia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... Feb. 21, 2017  IBM (NYSE: IBM ) Research has ... detect abnormalities of the eye,s retina. The Melbourne ... of Watson to recognize abnormalities in retina images, which could ... their early identification of patients who may be at risk ... of blindness in the developed world. The ...
(Date:2/21/2017)... , Feb. 21, 2017 Cognitive ... This technique is allowing a previously unattainable level ... Due to this ability, it is anticipated that ... US$ 4 Billion by 2022. The growth of ... advancements in computing platforms, rising installation of cognitive ...
(Date:2/21/2017)... 21, 2017 Scientists From Two ... by Plastic Industry  ... STEER, creator of advanced materials ... the fields of plastics, pharmaceuticals, food and nutraceuticals, biomaterials and ... Darmstadt, Germany , a leading science ...
Breaking Medicine Technology:
(Date:2/21/2017)... ... February 21, 2017 , ... Hanna Boys ... at PolicyLink, will be the keynote speaker at its second Professional Networking Breakfast ... Color Framework, which develops comprehensive strategies to create and expand opportunities for boys ...
(Date:2/21/2017)... ... February 21, 2017 , ... Individuals ... problems directly related to surgery, treatment, therapy and management. Regular exercise in proper ... qualities of life despite their diseases. On February 23, 2017, 1:00-2:00 p.m. E.S.T., ...
(Date:2/21/2017)... ... February 21, 2017 , ... ... coverage in veterinary medicine, will be launching its first bi-monthly issue of 2017 ... medicine, business and practice management, and One Health. , In making the ...
(Date:2/21/2017)... ... February 21, 2017 , ... Atlanta-based ... predictive analytic firm Predixion’s Healthcare IT practice. Predixion, which raised $42M+ to date, ... by giants including Accenture, GE Ventures, and Software AG , will bring ...
(Date:2/21/2017)... ... February 21, 2017 , ... A February 6 article on Healio ... It found that the treatments have led to significant improvements in weight loss and ... efforts. It also noted very few problematic results relating to the treatment. Beverly Hills ...
Breaking Medicine News(10 mins):